Updating Formularies: Considerations for Dry Eye Disease

EP: 1.Overview of Dry Eye Disease (DED) Causes and Treatments

EP: 2.Adverse Events & Existing Treatment Options for Dry Eye Disease

EP: 3.Navigating Different Subtypes of Dry Eye Disease

EP: 4.Assessing Efficacy of Treatment Through Patient-Reported Outcomes

Now Viewing

EP: 5.Updating Formularies: Considerations for Dry Eye Disease

EP: 6.Assessing the Economic Burden of Under Diagnosed Dry Eye Disease

EP: 7.Identifying Key Socioeconomic Burdens Associated with Dry Eye Disease

EP: 8.Resource Allocation in the Treatment of Dry Eye Disease

EP: 9.Quality of Life & Patient Reported Outcomes in Dry Eye Disease

EP: 10.Annual Health Care Costs of Managing Dry Eye Disease

EP: 11.Novel Treatments Targeting Symptoms & Causes of Dry Eye Disease

EP: 12.Evaluating Treatment Outcomes in Dry Eye Disease

EP: 13.Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease

EP: 14.Concluding Thoughts on the Treatment of Dry Eye Disease

This is a video synopsis/summary of a Stakeholder Summit involving:

Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.

Parekh discusses the high prevalence of dry eye disease (DED), accelerated by digital device use and mask wearing during COVID-19. Resulting issues like eye fatigue and secondary keratitis lead to lost workplace productivity, both outside and remote settings. The worldwide DED market represents billions in costs. Various pipeline innovations signal the broad need for a multidimensional treatment landscape to address heterogeneous DED subtypes. Lack of early DED control risks long-term visual impairment. Comprehensive DED insurance coverage is thus as warranted as for other chronic diseases to optimize outcomes and costs.

Kabiri notes secondary issues like neurotrophic keratitis and the need for treatments like serum tears after DED progression require high costs. Earlier control of the evaporative DED component could prevent downstream issues in a more cost-effective manner. Haumschild concurs, highlighting the high costs of uncontrolled DED, including greater health care utilization, lost workplace productivity, and staff shortages. Optimal DED management early on can mitigate adverse outcomes and costs.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.